Jacks Lab investigations published in Cancer Cell have identified a promising three-drug combination to improve pancreatic tumors’ response to immunotherapy. The team now seeks to analyze which tumors will respond best to this approach and is working with the Lustgarten Foundation for Pancreatic Cancer Research and two pharmaceutical companies to test the combination therapy in clinical trials.